FOLH1 folate hydrolase 1
ENSG00000086205 · protein coding · Open Targets profile
Has both folate hydrolase and N-acetylated-alpha-linked- acidic dipeptidase (NAALADase) activity. Has a preference for tri- alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, High-Quality Pocket, Druggable Family
- Antibody
- Advanced Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Small Molecule Binder
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.5749300122261047 (upper bound 0.7212200164794922). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 22 registry trials, updated in the last three years, of the most advanced drugs against FOLH1 (lutetium lu-177 vipivotide tetraxetan, HUJ591 111IN, HUJ591 177LU, MDX-070), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Michael SchweizerFred Hutch/University of Washington Cancer Consortium · 3 of 3 trials Phase 2+Ph2NCT07698535 · Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trialbrief
- Jeremie CalaisUCLA / Jonsson Comprehensive Cancer Center · 2 of 2 trials Phase 2+
- Praful RaviDana-Farber Cancer Institute · 1 of 2 trials Phase 2+
- Amar KishanUCLA / Jonsson Comprehensive Cancer Center · 1 of 1 trials Phase 2+
- Angela Castellanos RodriguezFred Hutch/University of Washington Cancer Consortium · 1 of 1 trials Phase 2+
- David WiseNYU Langone Health · 1 of 1 trials Phase 2+
- Jacob E BerchuckEmory University Hospital/Winship Cancer Institute · 1 of 1 trials Phase 2+
- Mark SteinColumbia University · 1 of 1 trials Phase 2+
- Matthew K. TollefsonMayo Clinic in Rochester · 1 of 1 trials Phase 2+
- Matthew P. ThorpeMayo Clinic in Rochester · 1 of 1 trials Phase 2+
- Rana McKayAlliance for Clinical Trials in Oncology · 1 of 1 trials Phase 2+
- Scott T TagawaWeill Medical College of Cornell University · 1 of 1 trials Phase 2+
- Thomas HopeAlliance for Clinical Trials in Oncology · 1 of 1 trials Phase 2+
- Alex Chehrazi-RaffleCity of Hope Medical Center · 0 of 1 trials Phase 2+
- Kirk A FreyUniversity of Michigan Rogel Cancer Center · 0 of 1 trials Phase 2+
Registry trials of lutetium lu-177 vipivotide tetraxetan, HUJ591 111IN, HUJ591 177LU, MDX-070 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 19 of 21 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 1 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
1 trials of drugs against FOLH1 were stopped early
Terminated, withdrawn and suspended interventional trials of lutetium lu-177 vipivotide tetraxetan, HUJ591 111IN, HUJ591 177LU, MDX-070, MLN-2704, CYT-500 177LU, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 1 most recent of 1.
- suspended · 2026-08-20 · Mayo Clinic · matched by the registry's drug synonyms“Pending additional funding.”
Paediatric incentives and obligations for FOLH1's drugs
For lutetium lu-177 vipivotide tetraxetan, HUJ591 111IN, HUJ591 177LU, MDX-070, MLN-2704, CYT-500 177LU: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · FOLH1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names lutetium lu-177 vipivotide tetraxetan, huj591 111in, huj591 177lu, mdx-070, mln-2704, cyt-500 177luRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names lutetium lu-177 vipivotide tetraxetan, huj591 111in, huj591 177lu, mdx-070, mln-2704, cyt-500 177luRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of lutetium lu-177 vipivotide tetraxetan, huj591 111in, huj591 177lu, mdx-070, mln-2704, cyt-500 177luRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of lutetium lu-177 vipivotide tetraxetan, huj591 111in, huj591 177lu, mdx-070, mln-2704, cyt-500 177luRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 3 interventional studies of lutetium lu-177 vipivotide tetraxetan, huj591 111in, huj591 177lu, mdx-070, mln-2704, cyt-500 177lu include patients under 18; 2 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 6 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.